Lyka Labs Limited Financial Ratios
LYKALABS · Healthcare · Current price ₹87.79
P/E ratio
-32.3x
P/B ratio
3.3x
ROE
-10.9%
ROCE
-6.0%
Debt / Equity
0.52
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | -32.3x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 3.3x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | -10.9% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | -6.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.52 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Lyka Labs Limited's latest numbers.
Lyka Labs Limited profitability
Lyka Labs Limited generates a return on equity of -10.9% and a return on capital employed of -6.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.52 and a P/E of -32.3x, Lyka Labs Limited is moderately leveraged. Our overall business-quality score for the company is 3.8 / 10.
Understand the ratios
More on Lyka Labs Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.